

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Sep 2026

### A comparative study on the effect of oral Magnesium supplementation versus placebo on Hypertension in patients with type 2 diabetes

#### Protocol summary

##### Study aim

Randomized allocation of patients with type 2 diabetes and hypertension to standard treatment with or without oral magnesium, with measurement of systolic and diastolic blood pressure

##### Design

A total of 30 participants per group will be enrolled consecutively based on eligibility criteria. Sample size was calculated as 26 per group using G\*Power 3.1.9.7 (effect size = 0.8, 80% power, 95% confidence) and increased to 30 per group to account for potential dropouts. Participants will be randomly assigned to receive either oral magnesium supplementation or placebo)

##### Settings and conduct

Patients with type 2 diabetes and hypertension attending the Internal Medicine Clinic of LOGHMAN Hakim Hospital (2025-2026) will be enrolled. Those on Valsartan/Amlodipine and insulin analogs will, after informed consent, be randomly assigned to standard treatment with or without oral magnesium. Follow-up occurs at weeks 4 and 8, with blood pressure measured using a manual manometer

##### Participants/Inclusion and exclusion criteria

Patients with type 2 diabetes and hypertension without prior gastrointestinal complications

##### Intervention groups

Patients aged 30 to 70 years with type 2 diabetes (diagnosed according to ADA criteria) who are treated with insulin analogs and who also have high blood pressure and are treated with valsartan/amlodipine, if they do not meet the exclusion criteria will be included in the study after obtaining informed written consent. After randomization, patients are assigned to two groups receiving oral magnesium citrate and placebo, and their blood pressure is assessed at baseline, four and eight weeks later.

##### Main outcome variables

Systolic blood pressure; Diastolic blood pressure; Fasting

blood glucose; HbA1c; Serum magnesium; Adverse events (diarrhea, hypotension, arrhythmia)

#### General information

##### Reason for update

##### Acronym

HTN

##### IRCT registration information

IRCT registration number: **IRCT20230522058258N2**

Registration date: **2026-01-02, 1404/10/12**

Registration timing: **prospective**

Last update: **2026-01-02, 1404/10/12**

Update count: **0**

##### Registration date

2026-01-02, 1404/10/12

##### Registrant information

##### Name

Arezoo Ranjbar Arani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 4427 0497

##### Email address

arezoo.ranjbar@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2026-01-04, 1404/10/14

##### Expected recruitment end date

2026-05-04, 1405/02/14

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
A comparative study on the effect of oral Magnesium supplementation versus placebo on Hypertension in patients with type 2 diabetes

**Public title**  
The effect of oral Magnesium supplementation on Hypertension in patients with type 2 diabetes

**Purpose**  
Diagnostic

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Diagnosis of type 2 diabetes mellitus according to the American Diabetes Association (ADA) criteria Controlled or uncontrolled hypertension under pharmacological treatment Provision of written informed consent Presence of severe renal disease (eGFR < 30 ml/min/1.73 m<sup>2</sup>) Presence of heart failure classified as New York Heart Association (NYHA) class III or IV History of magnesium supplementation or use of medications affecting serum magnesium levels Systolic blood pressure < 90 mmHg or blood pressure ≥ 160/90 mmHg at baseline requiring therapeutic intervention or medication adjustment Pregnancy Presence of gastrointestinal disorders that impair magnesium absorption  
**Exclusion criteria:**

**Age**  
From **30 years** old to **70 years** old

**Gender**  
Both

**Phase**  
3

**Groups that have been masked**  

- Participant
- Care provider

**Sample size**  
Target sample size: **60**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
The steps of random assignment of patients to two experimental and control groups will be as follows: 1- Creating a random sequence of Random Sequence Generation will be done in the form of simple randomization and through the preparation and shuffling of cards. So that a number of cards will be prepared as the first group and the same number of cards will be prepared for the next groups. Then, by removing them, a card is taken out and its assignment is registered, and that card is returned to the other cards. Then the cards are dealt again and another card is drawn. This process will continue until reaching a random sequence according to the sample size. 2- Random allocation concealment will be done by placing the aforementioned cards inside Sequentially Numbered Sealed Opaque Envelopes (SNOSE). 3- People from the research team

who are responsible for the above steps will not enter the other steps of the research, especially the examination of people in terms of the dependent variable.

**Blinding (investigator's opinion)**  
Single blinded

**Blinding description**  
either the intervention group (magnesium supplementation) or the control group (placebo). The magnesium supplement and placebo are identical in appearance and packaging and are coded accordingly. Investigators and healthcare personnel are aware of group allocation and are responsible for administering the intervention and patient follow-up. Access to the allocation codes by the Data Safety and Monitoring Committee, if established, will be permitted only when required for safety reasons. All participants provide written informed consent prior to enrollment.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

**Secondary Ids**  
empty

**Ethics committees**  
**1**  
**Ethics committee**  
**Name of ethics committee**  
Ethics committee of Sahid Beheshti University of Medical Sciences  
**Street address**  
Loqman Hakim hospital - special St. - Lashgar intersection  
**City**  
تهران  
**Province**  
Tehran  
**Postal code**  
1333635445  
**Approval date**  
2025-12-09, 1404/09/18  
**Ethics committee reference number**  
IR.SBMU.MSP.REC.1404.602

## Health conditions studied

**1**  
**Description of health condition studied**  
Hypertension  
**ICD-10 code**  
I10  
**ICD-10 code description**  
Essential (primary) hypertension

## Primary outcomes

### 1

#### Description

Systolic Blood Pressure

#### Timepoint

Before the intervention and 1 and 2 months after the intervention

#### Method of measurement

Sphygmomanometer

### 2

#### Description

Diastolic blood pressure

#### Timepoint

Before the intervention and 1 and 2 months after the intervention

#### Method of measurement

Sphygmomanometer

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: They are treated with 300 mg of oral magnesium daily for 2 months

#### Category

Treatment - Drugs

### 2

#### Description

Control group: they are treated with a placebo for 2 months.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Loghman Hakim Hospital

##### Full name of responsible person

Arezoo Ranjbar Arani

##### Street address

Loghman Hakim Hospital, Kamali St., South Kargar Ave.

##### City

تهران

##### Province

Tehran

##### Postal code

1333625445

#### Phone

+98 21 5541 7243

#### Email

drranjbar.ar@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences

##### Full name of responsible person

Afshin Zarghi

##### Street address

Yaman St, Velenjak St, Shahid Chamran Highway

##### City

Tehran

##### Province

Tehran

##### Postal code

1985717443

##### Phone

+98 21 2243 9770

##### Email

info@sbmu.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Shahid Beheshti University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences

##### Full name of responsible person

Arezoo Ranjbar Arani

##### Position

Associate professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Internal Medicine

##### Street address

Loghman Hakim Hospital, Kamali St., South Kargar Ave.

##### City

تهران  
**Province**  
Tehran  
**Postal code**  
1333625445  
**Phone**  
+98 21 5541 7243  
**Email**  
drranjbar.ar@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Arezo Ranjbar Arani  
**Position**  
Associate professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
Loghman hakim Hospital, Kamali Street, South Karegar Avenue  
**City**  
تهران  
**Province**  
Tehran  
**Postal code**  
1333625445  
**Phone**  
+98 21 5541 9005  
**Email**  
drranjbar.ar@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Arezo Ranjbar Arani  
**Position**  
Associate professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
Loghman Hakim Hospital, Kamali Ave, South Kargar

St  
**City**  
تهران  
**Province**  
Tehran  
**Postal code**  
1333625445  
**Phone**  
+98 21 5541 7243  
**Email**  
drranjbar.ar@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

### Title and more details about the data/document

All variables and information about participants can be shared after de-identifying people

### When the data will become available and for how long

At the time of publication

### To whom data/document is available

All treatment staff, researchers and people who intend to verify the data will be able to access the data

### Under which criteria data/document could be used

If the source is mentioned, the data will be made available to the requesters

### From where data/document is obtainable

Refer to the organizers of the plan or to Loghman Hakim Hospital in Tehran

### What processes are involved for a request to access data/document

The request is made by email or phone and the information will be sent in the form of e-mail

### Comments